108 related articles for article (PubMed ID: 27423613)
21. Fatal accidents among Danes with multiple sclerosis.
Brønnum-Hansen H; Hansen T; Koch-Henriksen N; Stenager E
Mult Scler; 2006 Jun; 12(3):329-32. PubMed ID: 16764347
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis outcome and morbi-mortality of a Brazilian cohort patients.
Alves-Leon SV; Malfetano FR; Pimentel ML; Estrada CL; Pereira VC; Liem AM; Novis SA
Arq Neuropsiquiatr; 2008 Sep; 66(3B):671-7. PubMed ID: 18949260
[TBL] [Abstract][Full Text] [Related]
23. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
[TBL] [Abstract][Full Text] [Related]
24. Balance performance in three forms of multiple sclerosis.
Soyuer F; Mirza M; Erkorkmaz U
Neurol Res; 2006 Jul; 28(5):555-62. PubMed ID: 16808889
[TBL] [Abstract][Full Text] [Related]
25. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
26. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
27. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
[TBL] [Abstract][Full Text] [Related]
28. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
29. Immunological differences between classical phenothypes of multiple sclerosis.
Iwanowski P; Losy J
J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
[TBL] [Abstract][Full Text] [Related]
30. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.
Eriksson M; Andersen O; Runmarker B
Mult Scler; 2003 Jun; 9(3):260-74. PubMed ID: 12814173
[TBL] [Abstract][Full Text] [Related]
32. Survival and cause of death in multiple sclerosis: a prospective population-based study.
Hirst C; Swingler R; Compston DA; Ben-Shlomo Y; Robertson NP
J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1016-21. PubMed ID: 18303108
[TBL] [Abstract][Full Text] [Related]
33. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
[TBL] [Abstract][Full Text] [Related]
34. Causes of death among persons with multiple sclerosis.
Cutter GR; Zimmerman J; Salter AR; Knappertz V; Suarez G; Waterbor J; Howard VJ; Marrie RA
Mult Scler Relat Disord; 2015 Sep; 4(5):484-490. PubMed ID: 26346799
[TBL] [Abstract][Full Text] [Related]
35. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.
Leray E; Vukusic S; Debouverie M; Clanet M; Brochet B; de Sèze J; Zéphir H; Defer G; Lebrun-Frenay C; Moreau T; Clavelou P; Pelletier J; Berger E; Cabre P; Camdessanché JP; Kalson-Ray S; Confavreux C; Edan G
PLoS One; 2015; 10(7):e0132033. PubMed ID: 26148099
[TBL] [Abstract][Full Text] [Related]
36. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
37. Progression in familial and nonfamilial MS.
Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
[TBL] [Abstract][Full Text] [Related]
38. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
39. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
40. Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Basque Country, Spain.
Rodríguez-Antigüedad Zarranz A; Mendibe Bilbao M; Llarena González C; Audicana C
Neuroepidemiology; 2014; 42(4):219-25. PubMed ID: 24821604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
